Minerva Neurosciences (NERV) Notes Payables (2013 - 2018)
Minerva Neurosciences' (NERV) quarterly Notes Payables came in at $1.4 million in Q2 2018, down 72.43% YoY from $5.1 million in Q2 2017, and down 48.21% on a QoQ basis from $2.7 million in Q1 2018.
Analysis
Minerva Neurosciences (NERV) Notes Payables (2013 - 2018) Analysis & Trends
Minerva Neurosciences (NERV) has 6 years of Notes Payables data on file, last reported at $1.4 million in Q2 2018.
- Quarterly Notes Payables fell 72.43% year-over-year to $1.4 million in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $1.4 million (down 72.43% YoY) and the FY2017 annual result came in at $4.0 million, down 18.36% from the prior year.
- Notes Payables eased to $1.4 million in Q2 2018, from $2.7 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $5.2 million in Q3 2017 to a low of $158263.0 in Q1 2015.
- A 5-year average of $3.0 million and a median of $2.7 million in 2018 frame the typical range for Notes Payables.
- Annual changes were most pronounced in 2016 — Notes Payables jumped 1788.21% — and 2018, when it sank 72.43%.
- Tracing NERV's Notes Payables over 5 years: stood at $2.0 million in 2014, then slipped by 28.53% to $1.4 million in 2015, then jumped by 238.3% to $4.9 million in 2016, then declined by 18.36% to $4.0 million in 2017, then tumbled by 64.75% to $1.4 million in 2018.
- The last three Notes Payables figures came in at $1.4 million (Q2 2018), $2.7 million (Q1 2018), and $4.0 million (Q4 2017), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2018 | 1.40 Mn |
| Mar 31, 2018 | 2.70 Mn |
| Dec 31, 2017 | 3.96 Mn |
| Sep 30, 2017 | 5.19 Mn |
| Jun 30, 2017 | 5.07 Mn |
| Mar 31, 2017 | 4.96 Mn |
| Dec 31, 2016 | 4.85 Mn |
| Sep 30, 2016 | 4.75 Mn |
| Jun 30, 2016 | 3.88 Mn |
| Mar 31, 2016 | 2.64 Mn |
| Dec 31, 2015 | 1.43 Mn |
| Sep 30, 2015 | 251,594.00 |
| Jun 30, 2015 | 1.09 Mn |
| Mar 31, 2015 | 158,263.00 |
| Jun 30, 2014 | 2.01 Mn |
| Dec 31, 2013 | 58,270.00 |